Practical detection of a definitive biomarker panel for Alzheimer's disease: comparisons between matched plasma and cerebrospinal fluid

Article, Other literature type English OPEN
Richens, Joanna L. ; Vere, Kelly-Ann ; Light, Roger A. ; Soria, Daniele ; Garibaldi, Jonathan ; Smith, A. David ; Warden, Donald ; Wilcock, Gordon ; Bajaj, Nin ; Morgan, Kevin ; O’Shea, Paul (2014)
  • Publisher: e-Century Publishing Corporation
  • Subject: Original Article

Previous mass spectrometry analysis of cerebrospinal fluid (CSF) has allowed the identification of a panel of molecular markers that are associated with Alzheimer’s disease (AD). The panel comprises Amyloid beta, Apolipoprotein E, Fibrinogen alpha chain precursor, Keratin type I cytoskeletal 9, Serum albumin precursor, SPARC-like 1 protein and Tetranectin. Here we report the development and implementation of immunoassays to measure the abundance and diagnostic capacity of these putative biomarkers in matched lumbar CSF and blood plasma samples taken in life from individuals confirmed at post-mortem as suffering from AD (n = 10) and from screened ‘cognitively healthy’ subjects (n = 18). The inflammatory components of Alzheimer’s disease were also investigated. Employment of supervised learning techniques permitted examination of the interrelated expression patterns of the putative biomarkers and identified inflammatory components, resulting in biomarker panels with a diagnostic accuracy of 87.5% and 86.7% for the plasma and CSF datasets respectively. This is extremely important as it offers an ideal high-throughput and relatively inexpensive population screening approach. It appears possible to determine the presence or absence of AD based on our biomarker panel and it seems likely that a cheap and rapid blood test for AD is feasible.
  • References (34)
    34 references, page 1 of 4

    [19] [20] Prvulovic D and Hampel H. Amyloid beta (Abeta) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin Chem Lab Med 2011; 49: 367- 374.

    Ewers M, Mielke MM and Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 2010; 45: 75-79.

    Alzheimers Dement 2008; 4: 38-48.

    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B and Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393.

    Schneider P, Hampel H and Buerger K. Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 2009; 15: 358-374.

    Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.

    Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, Hansson O, Miles AK, Janciauskiene SM, Warden D, Smith AD, Wilcock G, Kalsheker N, Rees R, Matharoo-Ball B and Morgan K. Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid. J Alzheimers Dis 2012; 28: 625-636.

    Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C and Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010; 67: 739-748.

    Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study. Alzheimers Res Ther 2011; 3: 5.

    [21] Quinlan JR. C4.5: programs for machine learning. Morgan Kaufmann Publishers Inc., 1993.

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark